“Switching from Dupilumab to Upadacitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b 4 LEVEL UP Study”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s451, https://doi.org/10.25251/skin.8.supp.451.